Serum osteopontin predicts the response to atezolizumab plus bevacizumab in patients with hepatocellular carcinoma.
Yamauchi R, Ito T, Yoshio S, Yamamoto T, Mizuno K, Ishigami M, Kawashima H, Yasuda S, Shimose S, Iwamoto H, Yamazoe T, Mori T, Kakazu E, Kawaguchi T, Toyoda H, Kanto T.
Yamauchi R, et al. Among authors: kakazu e.
J Gastroenterol. 2023 Jun;58(6):565-574. doi: 10.1007/s00535-023-01985-w. Epub 2023 Mar 30.
J Gastroenterol. 2023.
PMID: 36991155